Lyra Therapeutics Q1 net loss $22.5M; ENLIGHTEN 1 Phase 3 results expected in May 2024

Lyra Therapeutics, Inc.

2024-Q1 EPS reported -$0.35 revenue$532,000

Cash $87.1M at March 31, 2024 vs $102.8M at Dec 31, 2023; cash runway into Q1 2025.
Net loss $22.5M vs $16.3M in Q1 2023; R&D expense $18.2M (up $5.6M YoY).
ENLIGHTEN 1 pivotal Phase 3 data for LYR-210 in CRS expected in May 2024.
ENLIGHTEN 2 enrollment completion expected H2 2024; LYR-220 end-of-Phase 2 meeting with FDA anticipated H2 2024.
BEACON Phase 2 data for LYR-220 to be presented at COSM on May 15, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lyra Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023..

Period: first quarter ended March 31, 2024
Net income: Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023.
Result: reported results

Exact text from the filing

Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-050525

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.